Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines

Everolimus (Eve) is an FDA approved drug that inhibits mammalian target of rapamycin (mTOR). It is employed in breast cancer treatment even if its responsiveness is controversial. In an attempt to increase Eve effectiveness, we have developed a novel Eve nanoformulation exploiting H-ferritin nanocag...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonizzi, Arianna, Truffi, Marta, Sevieri, Marta, Allevi, Raffaele, Sitia, Leopoldo, Ottria, Roberta, Sorrentino, Luca, Sottani, Cristina, Negri, Sara, Grignani, Elena, Mazzucchelli, Serena, Corsi, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723888/
https://www.ncbi.nlm.nih.gov/pubmed/31382388
http://dx.doi.org/10.3390/pharmaceutics11080384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723888/
https://www.ncbi.nlm.nih.gov/pubmed/31382388
http://dx.doi.org/10.3390/pharmaceutics11080384

Ejemplares similares